Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy

Nomura, Hideyuki; Miyagi, Yugo; Tanimoto, Hironori; Yamashita, Nobuyuki; Ito, Kiyoaki; Masaki, Naohiko; Mizokami, Masashi

doi:10.1111/j.1440-1746.2012.07171.x

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ITPA SNPs were associated with RBV‐induced anaemia as well as IFN‐induced TCP . Severe haemoglobin reduction, which is mainly found in ITPA CC patients, was inversely correlated with platelet reduction, although the reasons for these associations were not clear.…”

Section: Discussionmentioning

confidence: 99%

Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia

Ogawa

Furusyo

Murata

et al. 2013

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Thrombocytopenia in patients with chronic hepatitis C may represent an obstacle for the initiation of antiviral treatment. The aim of this study was to evaluate factors predictive of successful pegylated interferon (PEG-IFN) α2b and ribavirin (RBV) treatment for patients with thrombocytopenia with no history of splenectomy or partial splenic embolization. One hundred and fifty-one chronic hepatitis C patients (genotype 1: n = 110, genotype 2: n = 41) with TCP (<100 × 10(9) /L) at baseline were enrolled. Pretreatment variables included interleukin 28B (IL28B) genotype (rs8099917) and homoeostasis model assessment of insulin resistance score (HOMA-IR). The kinetics of haemoglobin and platelets according to the inosine triphosphatase (ITPA) genotype (rs1127354) were investigated. Sustained virological response (SVR) was significantly more frequent in hepatitis C virus (HCV) genotype 2 (65.9%) than in genotype 1 (34.5%) patients (P < 0.0001). Multiple logistic regression analysis of HCV genotype 1 extracted IL28B TT genotype [odds ratio (OR) 5.97, P = 0.006] and HOMA-IR <2.5 (OR 7.14, P = 0.0016) as significant independent pretreatment predictors of SVR. The analyses of HCV genotype 2 showed that HOMA-IR was significantly related to SVR, but IL28B genotype was not. Patients with ITPA CC genotype showed a significant haemoglobin reduction and lower degree of platelets decrease than those with ITPA CA/AA genotypes. The most common reason for premature discontinuation of treatment was the development of hepatocellular carcinoma (n = 8, 5.3%). In conclusion, HOMA-IR is a useful predictor of SVR for patients with thrombocytopenia infected with HCV genotype 1 or 2 treated with PEG-IFNα2b and RBV. The inclusion of IL28B, ITPA genotypes and HOMA-IR adds valuable therapeutic information.

show abstract

Section: Discussionmentioning

confidence: 99%

Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia

Ogawa

Furusyo

Murata

et al. 2013

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

Successful Treatment of Hepatitis B Virus Reactivation With a Combination of Entecavir and Short-Term Administration of Interferon-β Twice per Day

Sasaki,

Hirose,

Suetsugu

et al. 2024

Cureus

View full text Add to dashboard Cite

Hepatitis B virus (HBV) reactivation-related hepatitis is likely to progress to acute liver failure, with high morbidity and mortality, even when nucleoside analogs are administered after the onset of hepatitis. We report a case of adult T-cell leukemia/lymphoma (ATLL) with the development of HBV reactivation-related hepatitis during chemotherapy and successful treatment by a combination of entecavir and short-term intravenous administration of interferon (IFN)-β 3 MIU twice per day. This outcome suggests that this combination therapy has a potent effect in rapidly suppressing HBV replication in the early phase of hepatitis and may be effective and safe for the treatment of HBV reactivation-related hepatitis.

show abstract

Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy

Abstract: Natural IFN-β/ribavirin therapy is safe for patients with the ITPA-CC genotype, even if their pretreatment platelet counts are low.

Cited by 2 publications

References 23 publications

Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia

Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia

Successful Treatment of Hepatitis B Virus Reactivation With a Combination of Entecavir and Short-Term Administration of Interferon-β Twice per Day

Contact Info

Product

Resources

About